- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Syntara Ltd (SNT)
The Syntara share price today is 0.028, view ASX SNT stock exchange data. Track the latest Syntara share price with real-time updates on SNT stock performance including market cap, day range, 52-week range and dividend yield. Access SNT charts, earnings dates and analyst estimates to support your investment decisions.
Sydney
Currency in AUD
0.028
+0.001(+3.70%)
Delayed Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.028
0.028
52 wk Range
0.023
0.083
SNT is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.0280.028
52 wk Range
0.0230.083
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
SNT Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
0.125
Upside
+346.43%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 0.125
(+346.43% Upside)
Syntara Ltd Earnings Call Summary for Q3/2025
- Syntara reported $18M cash balance, providing 18-month runway; stock up 3.57% to $3.42 amid investor optimism
- Lead drug 5505 targets myelofibrosis market valued at $1.9B; company exploring partnerships for clinical studies
- Key data presentation expected at European Hematology Association meeting in June; FDA guidance anticipated by Q3
- Revenue growth of 9.03% in last 12 months; stock near 52-week high of $3.97 with 144.29% return over past year
- Potential risks include delays in MDS trial initiation, critical FDA outcomes, and competitive pressure from JAK inhibitors
Last Updated: 01-05-2025, 07:44 am
Read Full TranscriptEarnings
Latest Release
05-05-2026
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
Compare SNT to Peers and Sector
Metrics to compare | SNT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSNTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.4x | −9.0x | −0.5x | |
PEG Ratio | −0.18 | 0.12 | 0.00 | |
Price/Book | 4.2x | 5.6x | 2.6x | |
Price / LTM Sales | 5.9x | 28.5x | 3.2x | |
Upside (Analyst Target) | 363.0% | 115.4% | 47.8% | |
Fair Value Upside | Unlock | 1.7% | 5.9% | Unlock |
Syntara Limited operates as a clinical-stage drug development company that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate, amsulostat, is being developed for the treatment of bone marrow cancer myelofibrosis and is in Phase 1c/2 studies for patients with myelodysplastic syndrome. The company also develops topical pan-LOX inhibitors with SNT-9465, which is in a Phase 1a/b study for hypertrophic scars; SNT-6302 for keloid scars; and SNT-4728 to treat sleep disorders and slow progression of neurodegenerative diseases by reducing neuroinflammation. In addition, it develops other drug candidates that target fibrotic and inflammatory diseases, including kidney fibrosis, MASH, pulmonary fibrosis, and cardiac fibrosis. The company was formerly known as Pharmaxis Ltd and changed its name to Syntara Limited in December 2023. Syntara Limited was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Syntara (SNT) Share Price Today?
The Syntara share price today is 0.028.
What is the current Syntara (SNT) share price and day range?
As of 06-05-2026, the Syntara share price is 0.028, with a previous close of 0.027. The share price has ranged from 0.028 to 0.028 today, while the 52-week range spans from 0.023 to 0.083.
What Is the Syntara Market Cap?
As of today, Syntara market cap is 45.760M.
What Is the Syntara (SNT) Share Price Target?
The average 12-month share price target for Syntara is 0.125, with a high estimate of 0.19 and a low estimate of 0.06. 2 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +346.43% Upside potential.
What Is Syntara's Earnings Per Share (TTM)?
The Syntara EPS (TTM) is -0.009.
When Is the Next Syntara Earnings Date?
Syntara will release its next earnings report on 05-05-2026.
From a Technical Analysis Perspective, Is SNT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Syntara Trade On?
Syntara is listed and trades on the Sydney Stock Exchange.
What Is the Stock Symbol for Syntara?
The stock symbol for Syntara is "SNT."
How Many Times Has Syntara Stock Split?
Syntara has split 1 times.
How Many Employees Does Syntara Have?
Syntara has 21 employees.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.